Use Of Cannabinoids In The Treatment Of Epilepsy

  • Published: Jun 29, 2017
  • Earliest Priority: Jun 17 2014
  • Family: 37
  • Cited Works: 7
  • Cited by: 7
  • Cites: 0
  • Additional Info: Cited Works Full text
Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).


Claims
Owners (US)
CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Jun 29, 2017
  • Application: Mar 3, 2017
    US US 201715449084 A
  • Priority: Mar 3, 2017
    US US 201715449084 A
  • Priority: Oct 4, 2016
    US US 201615284766 A
  • Priority: Jun 17, 2015
    US US 201514741783 A
  • Priority: Apr 17, 2015
    GB GB 201506550 A
  • Priority: Jun 17, 2014
    GB GB 201410771 A

Sign in to the Lens

Feedback